Literature DB >> 32712014

We Can Finally Stop Worrying About SGLT2 Inhibitors and Acute Kidney Injury.

Vikas S Sridhar1, Katherine R Tuttle2, David Z I Cherney3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32712014     DOI： 10.1053/j.ajkd.2020.05.014

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN： 0272-6386            Impact factor:   8.860


× No keyword cloud information.
  9 in total

Review 1.  SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis.

Authors:  Hongyan Liu; Vikas S Sridhar; Bruce A Perkins; Julio Rosenstock; David Z I Cherney
Journal:  Curr Diab Rep       Date:  2022-05-28       Impact factor: 4.810

Review 2.  Is there any robust evidence showing that SGLT2 inhibitor use predisposes to acute kidney injury?

Authors:  Sidar Copur; Abdullah Yildiz; Carlo Basile; Katherine R Tuttle; Mehmet Kanbay
Journal:  J Nephrol       Date:  2022-08-13       Impact factor: 4.393

Review 3.  Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations.

Authors:  Kevin Yau; Atit Dharia; Ibrahim Alrowiyti; David Z I Cherney
Journal:  Kidney Int Rep       Date:  2022-05-05

Review 4.  Value of SGLT-2 inhibitors in the treatment of chronic kidney disease : Clinical and practical implications.

Authors:  Marcus Säemann; Daniel Cejka; Sabine Schmaldienst; Alexander R Rosenkranz; Gert Mayer
Journal:  Wien Klin Wochenschr       Date:  2022-10-17       Impact factor: 2.275

5.  The Adaptive Renal Response for Volume Homeostasis During 2 Weeks of Dapagliflozin Treatment in People With Type 2 Diabetes and Preserved Renal Function on a Sodium-Controlled Diet.

Authors:  Rosalie A Scholtes; Marcel H A Muskiet; Michiel J B van Baar; Anne C Hesp; Peter J Greasley; Ann Hammarstedt; Cecilia Karlsson; Karen M Hallow; A H Jan Danser; Hiddo J L Heerspink; Daniël H van Raalte
Journal:  Kidney Int Rep       Date:  2022-03-04

6.  Clinical Implications of an Acute Dip in eGFR after SGLT2 Inhibitor Initiation.

Authors:  Hiddo J L Heerspink; David Z I Cherney
Journal:  Clin J Am Soc Nephrol       Date:  2021-04-20       Impact factor: 10.614

Review 7.  Cardiorenal Protection in Diabetic Kidney Disease.

Authors:  Jason F Lee; Ecaterina Berzan; Vikas S Sridhar; Ayodele Odutayo; David Z I Cherney
Journal:  Endocrinol Metab (Seoul)       Date:  2021-04-19

8.  A Description of Acute Renal Failure and Nephrolithiasis Associated With Sodium-Glucose Co-Transporter 2 Inhibitor Use: A VigiBase Study.

Authors:  Ioana Frent; Daniel Leucuta; Camelia Bucsa; Andreea Farcas; Florin Casoinic; Cristina Mogosan
Journal:  Front Pharmacol       Date:  2022-08-08       Impact factor: 5.988

9.  Intravital imaging of hemodynamic glomerular effects of enalapril or/and empagliflozin in STZ-diabetic mice.

Authors:  Hannah Kroeger; Friederike Kessel; Jan Sradnick; Vladimir Todorov; Florian Gembardt; Christian Hugo
Journal:  Front Physiol       Date:  2022-09-12       Impact factor: 4.755
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.